Clinical trials: Herpangina
Hand, Foot and Mouth Disease, Herpangina
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
The Phase I clinical trial is divided into two parts. The first part uses an open-label design, while the second part uses a randomized, double-blind, and controlled design.
- Trial name
- NCT06063057
- Testing
- low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hand, Foot, and Mouth Disease(HFMD), Herpangina
Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
This multicenter, randomized, double-blind, placebo-controlled phase IIIa clinical trial aims to evaluate the protective efficacy , immunogenicity and safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in…
- Trial name
- NCT07611513
- Testing
- Tetravalent Inactivated Enterovirus Vaccine (Vero Cell)
- Where
- 5 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hand, Foot, and Mouth Disease (HFMD), Herpangina
Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
The trial aims to assess the tolerability, safety, and immunogenicity of the tetravalent inactivated enterovirus vaccine in adults and children aged 6 months to 12 years.
- Trial name
- NCT06754384
- Testing
- Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell), Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell), High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
- Where
- China
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hand, Foot and Mouth Disease, Herpangina
Surveillance of HFMD in Pediatric Outpatients
The aims of this prospective multicentric study is to determine the types of enteroviruses (EVs) responsible for hand, foot and mouth disease (HFMD) or herpangina in children seen within an ambulatory setting : to detect an…
- Conditions
- Hand, Foot and Mouth Disease, Herpangina, Enterovirus Infections
- Trial name
- PMB (NCT06263439)
- Testing
- Throat/buccal swab sample
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- University Hospital, Clermont-Ferrand
Herpangina, Gingivostomatitis
Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial
The purpose of this study is to see if sucralfate, a medication commonly used for patients with stomach ulcers, may help pediatric patients with mouth ulcers decrease their pain level and improve their ability to drink.
- Conditions
- Herpangina, Gingivostomatitis, Hand, Foot and Mouth Disease
- Trial name
- NCT03241030
- Testing
- Sucralfate, Acetaminophen, Ibuprofen
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Texas at Austin
Herpangina
Effect of Recombinant Human Interferon α-2b Spray on Herpangina
This is a multicenter, open，randomized controlled trial aiming to evaluate the effectiveness of recombinant human interferon α-2b spray compared with ribavirin treatment on pediatric patients with herpangina.
- Trial name
- NCT03266601
- Testing
- Recombinant Human Interferon α-2b Spray, Ribavirin
- Where
- China
- Volunteers
- 668 people
- Sponsor
- Children's Hospital of Fudan University
Hand Foot and Mouth Disease
Neurodevelopment Outcomes Following Severe Hand Foot and Mouth Disease in Vietnam
Hand Foot and Mouth Disease (HFMD) is a common infectious disease in childhood. Several enteroviruses are associated with the disease.
- Trial name
- 08RS (NCT02066714)
- Where
- Vietnam
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Hand, Foot and Mouth Disease, Herpangina
A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months
Since its discovery in 1969, enterovirus 71 (EV71) has been recognised as a frequent cause of epidemics of hand-foot-mouth disease (HFMD) associated with severe neurological sequelae in a small proportion of cases.
- Conditions
- Hand, Foot and Mouth Disease, Herpangina, Other EV71-associated Diseases
- Trial name
- NCT01508247
- Testing
- inactivated vaccine (Vero Cell) against EV71
- Where
- 4 sites in China
- Volunteers
- 10,245 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention